Abstract:The most common type of urinary bladder cancer is called as transitional cell carcinoma. The major risk factors for bladder cancer are environmental, tobacco smoking, exposure to toxic industrial chemicals and gases, bladder inflammation due to microbial and parasitic infections, as well as some adverse side-effects of medications. The genetic mutations in some chromosomal genes, such as FGFR3, RB1, HRAS, TP53, TSC1, and others, occur which form tumors in the urinary bladder. These genes play an important role in the regulation of cell division which prevents cells from dividing too quickly. The changes in the genes of human chromosome 9 are usually responsible for tumor in bladder cancer, but the genetic mutation of chromosome 22 can also result in bladder cancer. The identification of p53 gene mutation has been studied at NIH, Washington, DC, USA, in urine samples of bladder cancer patients. The invasive bladder cancers were determined for the presence of gene mutations on p53 suppressor gene. The 18 different bladder tumors were evaluated, and 11 (61 %) had genetic mutations of p53 gene. The bladder cancer studies have suggested that 70 % of bladder cancers involve a specific mutation in a particular gene, namely telomerase reverse transcriptase (TERT) gene. The TERT gene is involved in DNA protection, cellular aging processes, and cancer. The Urothelial carcinomas of the bladder have been described in Atlas of genetics and cytogenetics in oncology and hematology. HRAS is a proto-oncogene and has potential to cause cancer in several organs including the bladder. The TSC1 c. 1907 1908 del (E636fs) mutation in bladder cancer suggests that the location of the mutation is Exon 15 with frequency of TSC1 mutation of 11.7 %. The recent findings of BAP1 mutations have shown that it contributes to BRCA pathway alterations in bladder cancer. The discoveries of more gene mutations and new biomarkers and polymerase chain reaction bioassays for gene mutations in bladder cancer need further research.

The Frequency Of P53 Mutation In The Bladder Transitional Cell Carcinoma

Clinical Value of P_53 Gene Mutation in Bladder Cancer

Study on relationship between mutant p53 and multidrug resistance gene 1 in gastric cancer

The relationship of expression of p53,p21,Ki-67 and VEGF and bladder cancer stage,grade and prognosis

Relationship between the expression of mutant P53 and PCNA and their clinical significances in transitional cell carcinoma of the bladder

The Expression of p16 and p53 Tumor Suppressor Gene in Bladder Carcinoma

EXPRESSION OF P53 PRODUCT IN CHINESE HUMAN BLADDER-CARCINOMA

[Mechanism of P53 Gene Mutation in the Development of Urologic Cancer].

Silencing of Mutant P53 by Sirna Induces Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells

Expression of PML growth suppressor in bladder transitional cell carcinoma

The Relationship Between the Expression of Mutant p53 and VEGF and the Clinical Significances in Transitional Cell Carcinoma of the Bladder

The expression of 53 in cervical carcinoma

P53 Codon 72 Polymorphism in Cervical Cancers and Its Correlation with HPV16,18E6

Study of p16 gene loss and mutation in primary transitional cell carcinomas of urinary bladder

Expression of MMR and mutated p53 in sporadic colorectal carcinoma

Significance of Study on P16 Gene Loss in Primary Transitional Cell Carcinomas of Urinary Bladder

p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.

Expressions and clinical significances of PTEN and P53 gene in non-muscle-invasive bladder cancer

Bladder Cancer and Genetic Mutations

Prevalence and Predictive Value of P53 Mutation in Patients with Oesophageal Squamous Cell Carcinomas: a Prospective Clinico-Pathological Study and Survival Analysis of 70 Patients.

Expression of P53 Gene in Cervical Squamous Cell Carcinoma and Its Significance